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Background: Natural killer (NK) cells play a key role in non-specific immune response in different cancers, including
pancreatic cancer. However the anti-tumor effect of NK cells decreases during pancreatic cancer progression. The
regulatory pathways by which NK cells facilitate tumor immune escape are unclear, therefore our purpose was to
investigate the roles of the contributory factors.
Methods: NK cells isolated from fresh healthy peripheral blood were co-cultured with normal human pancreatic
ductal cells hTERT-HPNE and human pancreatic cancer cell lines SW1990 and BxPc-3 in vitro. Then NK cell function
was determined by Flow cytometric analysis of surface receptors and cytotoxic granules in NK cells, NK cell apoptosis
and cytotoxicity, and Enzyme-linked immunosorbent assay of cytokines. Expression level of MMP-9, IDO and COX-2 in
hTERT-HPNE and SW1990 cells were detected by quantitative RT-PCR. Statistical differences between data groups were
determined by independent t-tests using SPSS 19.0 software.
Results: Our results showed that NK cell function was significantly downregulated following exposure to pancreatic
cancer cells compared to normal pancreatic cells, as demonstrated by lower expressions of activating surface receptors
(NKG2D, DNAM-1, NKp30 and NKp46) and cytotoxic granules (Perforin and Granzyme B); decreased secretion of
cytokines (TNF-α and IFN-γ); and reduced cytotoxicity against myelogenous leukemia K562 cells. Further investigations
revealed that MMP-9 and IDO may be implicated in SW1990 cell-induced NK cell dysfunction by facilitating tumor
immune evasion. Blockade by TIMP-1 and/or 1-MT could partially restore NK function.
Conclusions: Taken together, elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates NK cell
dysfunction. Our findings could contribute to the development of NK cell-based immunotherapy in patients with
pancreatic cancer.
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Pancreatic cancer is one of the most common gastro-
intestinal malignancies worldwide and is the fifth leading
cause of cancer-related deaths [1]. It is characterized by
rapid progression and intrinsic and acquired drug resist-
ance [2]. Pancreatic cancer is difficult to diagnose in its
early stages, therefore the rate of surgical resection is* Correspondence: miaoyi@njmu.edu.cn; zhuyijssry@126.com
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unless otherwise stated.low (<20%) [3] and the five-year survival rate is poor (<6%)
[1]. The progression of pancreatic cancer is affected by the
surrounding microenvironment which largely consists of
cancer associated fibroblasts and infiltrating inflammatory
cells [4-6], including natural killer (NK) cells.
NK cells are key components in the innate immune
system, acting as the first line of defense in the body.
They are a type of cytotoxic lymphocyte that mediate a
pro-inflammatory response and are closely associated with
the progression of cancer, including pancreatic cancer [7].
Evidence shows that NK cells not only kill target cancer
cells directly, without prior sensitization [8,9], but also
by binding to specific surface ligands expressed on the
surface of cancer cells, such as major histocompatibilitytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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iveness of NK cells as anticancer agents depends not only
on the number of circulating, activated NK cells [11] but
also on the expression of activating surface receptors,
inhibitory surface receptors, cytotoxic granules and
cytokines. NK cell dysfunction has been reported in
several cancers, such as pancreatic cancer [7], gastric
cancer [12], and colorectal cancer [13]. Although cancer
cells have been shown to induce NK cell dysfunction via
downregulation of specific activating surface receptors
(e.g. NKG2D), natural cytotoxicity receptors (NCR) [14],
cytotoxic granules (e.g. Perforin and Granzyme B) [15],
decreased secretion of cytokines (e.g. TNF-α and IFN-γ)
[16] and upregulation of inhibitory surface receptors (e.g.
KIR3DL1 and KIR2DL1/DS1) [17,18], the underlying
mechanisms are largely unknown.
Several studies have suggested that matrix metallopep-
tidase 9 (MMP-9), a 92-kDa type IV collagenase which
is secreted by mesenchymal stem cells (MSC), can sig-
nificantly downregulate the cytotoxicity of NK cells
in vitro by targeting T cells [19,20]. Indoleamine 2, 3-
dioxygenase (IDO) has also been reported to play a role
in MSC-mediated immunosuppression [21] by inhibiting
NK cell accumulation and suppressing NK cell function
[22]. This suggests that MMP-9 and IDO may play similar
roles in tumor-induced NK cell dysfunction. Decreased
infiltration of inflammatory cells into the tumor micro-
environment has been associated with increased expression
of COX-2 [23], which is known to promote tumor
growth via its major product prostaglandin E2 (PGE2) in
a T cell or NK cell-dependent manner [24,25]. Together,
MMP-9, IDO and PGE2 are potent effectors in the inter-
action between pancreatic cancer cells and NK cells. The
mechanism by which they promote NK cell dysfunction is
the focus of this investigation.
Methods
Antibodies and reagents
Anti-human CD3-FITC/CD16 + 56-PE mixed antibody
were purchased from Beckman Coulter (Brea, CA,
USA). Anti-human CD16-FITC, NKG2D-PE, NKp44-
APC, DNAM-1-FITC, NKp46-Alexa Fluor 647, NK
p30-PE, KIR3DL1-FITC, KIR2DL1/DS1-PE, NKp30-
APC, Perforin-PE and Granzyme B-FITC antibodis
were all purchased from BioLegend (San Diego, CA,
USA), as well as Fixation Buffer, Wash Buffer, Annexin
V binding buffer, Alexa Fluor 647 Annexin V and 7-AAD
Viability Staining Solution. The MPP-9 and IDO inhibi-
tors were 1-Methyl-DL-tryptopan (1-MT; Sigma-Aldrich,
St. Louis, MO, USA) and Tissue inhibitor of metallopro-
teinases 1 (TIMP-1; PeproTech, Rocky Hill, NJ, USA).
Human NK Cell Isolation Kit was purchased from
Miltenyi Biotec (Auburn, CA, USA) and ELISA kits were
purchased from Abcam (Cambridge, MA, USA). Trizolreagent and PrimeScript RT Master Mix (Perfect Real
Time) were both obtained from TaKaRa (Shiga, Japan)
and Power SYBR Green PCR Master mix was purchased
from Applied Biosystems (Carlsbad, CA, USA).
NK cell isolation
Fresh peripheral blood samples from healthy volunteers
were provided by Jiangsu Province Blood Center (Gu Jian,
China). Peripheral blood mononuclear cells (PBMC) were
isolated by Ficoll-Hypaque density gradient centrifugation.
NK cells were selected from the PBMCs by negative mag-
netic selection. The purity of the NK cells was >92%, as
quantified by multicolor flow cytometry (Gallios; Beckman
Coulter).
Cells and cell culture
The normal human pancreatic ductal cell line hTERT-
HPNE and pancreatic cancer cell lines SW1990 and
BxPc-3 were obtained from the American Type Culture
Collection (ATCC; Rockville, MD, USA). The hTERT-
HPNE cells were cultured as previously described [26];
SW1990 and BxPc-3 cell lines were cultured in DMEM
supplemented with 10% FBS, penicillin (100 U/mL) and
streptomycin (100 μg/mL). The myelogenous leukemia
K562 cell line (ATCC) was cultured in RPMI 1640 sup-
plemented with 10% FBS, penicillin (100 U/mL) and
streptomycin (100 μg/mL). The NK-92 cell line was
kindly donated by Professor Bin Gao and was cultured
as previously described [27]. Purified NK cells were
cultured in 6-well plates (3 × 105 cells/well) in AIM-V
media supplemented with 10% FBS, penicillin (100 U/mL),
streptomycin (100 μg/mL) and interleukin 2 (IL-2; 100 U/
mL; PeproTech, Rocky Hill, NJ, USA), either in absence
or presence of hTERT-HPNE, SW1990 and BxPc-3 cells
(5 × 105 cells/well). In order to investigate the roles of
MMP-9 and IDO, NK-92 cells were co-cultured with
SW1990 cells in 6-well plates (NK-92/SW1990 ratio:
3 × 105/5 × 105 cells/well) in the presence of 0.5 ug/ml
TIMP-1 (a specific blocker for MMP-9) and/or 0.5 mM
1-MT (a specific blocker for IDO).
Flow cytometric analysis
NK and NK-92 cells, either cultured alone or co-cultured
with normal or cancer pancreatic cell lines, were harvested
after five days and divided into four tubes, labeled as
T1, T2, T3 and T4. Firstly, T1, T2, T3 and T4 was
respectively washed twice with PBS. Secondly, T1 was
stained with anti-human CD16-FITC, NKG2D-PE, and
NKp44-APC antibodies; T2 was stained with anti-human
DNAM-1-FITC, NKp30-PE, and NKp46- Alexa Fluor 647
antibodies; T3 was stained with anti-human KIR3DL1-
FITC, KIR2DL1/DS1-PE and NKp80-APC antibodies; T4
was added with 500 μl fixation Buffer and incubated in
the dark at room temperature for 20 min, and then, T4
Peng et al. BMC Cancer 2014, 14:738 Page 3 of 12
http://www.biomedcentral.com/1471-2407/14/738was washed twice with Wash Buffer and stained with anti-
human Granzyme-B-FITC, and Perforin-PE antibodies.
After incubating in the dark at room temperature for
15 min, the cells were washed twice with PBS. After
staining, the tubes were incubated in the dark at room
temperature for 15 min and washed twice with PBS.
Lastly, all tubes were analyzed by multicolor flow cytome-
try. Data were analyzed using Kaluza software.
Apoptosis of NK cells
NK cells, either cultured alone or co-cultured with normal
or cancer pancreatic cell lines, were harvested after threeFigure 1 Comparisons between NK cells cultured alone and those cul
cancer BxPc-3 and SW1990 cells. (A and B) The percentages of surface r
the different NK cell-pancreatic cell cultures. (C–I) Comparisons between th
experiments were repeated three times. All data were expressed as mean ±
19.0 software. *represents P <0.05, **represents P <0.01, and ***representsdays and resuspended in 500 μL Annexin V binding buffer.
The cells were stained with 5 μL Alexa Fluor 647 Annexin
V and 7-AAD Viability Staining Solution and incubated
in the dark at room temperature for 15 min before being
analyzed by multicolor flow cytometry.
Apoptosis of K562 cells
NK and NK-92 cells, either cultured alone or co-cultured
with normal or cancer pancreatic cell lines, were har-
vested after three days. K562 cells were treated with the
harvested NK or NK-92 cells were in the presence of IL-2
(100 U/mL) for 2 h at different effector-to-target (E/T;tured with normal pancreatic hTERT-HPNE cells or pancreatic
eceptor-positive and cytotoxic granule-positive NK cells harvested from
e percentages of positive NK cells in the different culture groups. All
SD. Independent t-tests were used for statistical analysis through SPSS
P <0.001.
Figure 2 (See legend on next page.)
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Figure 2 The influence of pancreatic cancer cells on the apoptosis, cytotoxic activity, and cytokines secretion of NK cells. (A and B)
Percentages of apoptotic NK cells exposed to normal pancreatic cells compared those exposed to pancreatic cancer cells. (C) Flow cytometric
analysis of the percentages of apoptotic K562 cells treated with NK cells, either cultured alone or with normal pancreatic cells or cancer cells, at
an effector-to-target (E/T) ratio of 9:1. (D) The percentages of apoptotic K562 cells at different E/T ratios (1:1, 3:1, and 9:1) show a significant
decrease in K562 cell apoptosis after treatment with NK cells exposed to pancreatic cancer cells compared to those exposed to normal pancreatic
cells. (E, F, and G). The concentrations of GM-CSF, TNF-α and IFN-γ in the supernatants from the different NK cell-pancreatic cell culture groups.
All experiments were repeated three times. All data were expressed as mean ± SD. Independent t-tests were used for statistical analysis through
SPSS 19.0 software. *represents P <0.05, **represents P <0.01, and ***represents P <0.001.
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and stained with CD3-FITC/CD(16 + 56)-PE, incubated in
the dark at room temperature for 15 min, washed 2 times
with PBS and resuspended in 500 μL Annexin V binding
buffer. The cells were stained with 5 μL Alexa Fluor 647
Annexin V and 7-AAD Viability Staining Solution and
incubated in the dark at room temperature for a further
15 min. According to cells staining, cell subset which
detected as CD3-/CD(16 + 56) + was NK cells, and another
cell subset which detected as CD3-/CD(16 + 56)- was K562
cells. Percentage of apoptosis K562 cells before was ana-
lyzed by multicolor flow cytometry.
Enzyme-linked immunosorbent assay (ELISA)
The expression of some protein (IDO, MMP-9, GM-CSF,
TNF-α, and IFN-γ) were detected by ELISA. The concen-
trations of MMP-9 and IDO in cell culture supernatants
(NK cells cultured alone, hTERT-HPNE cells cultured
alone or co-cultured with NK cells, SW1990 cells cultured
aloneor co-cultured with NK cells; and NK-92 cells
cultured alone or co-cultured with SW1990 cells in the
absence or presence of TIMP-1 and/or 1-MT) were deter-
mined by specific ELISA kits. The concentrations of
GM-CSF, TNF-α and IFN-γ in cell culture supernatants
(NK cells cultured alone or co-cultured with hTERT-
HPNE and SW1990 cells; and NK-92 cultured alone or
co-cultured with SW1990 cells in the absence or presence
of TIMP-1 and/or 1-MT) were also determined. All pro-
cedures were carried out according to the manufacturer’s
protocols.
Quantitative real-time reverse-transcription polymerase
chain reaction (qRT-PCR)
Total RNA was extracted from hTERT-HPNE or SW1990
cells cultured alone or co-cultured with NK cells using
Trizol reagent and reverse-transcribed to cDNA using
PrimeScript RT Master Mix (Perfect Real Time). The
cDNA was amplified using Power SYBR Green PCR
Master mix and the Step One Plus Real-Time PCR System
(Applied Biosystems, Carlsbad, CA, USA). Each procedure
was performed according to the manufacturer’s instruc-
tions. The sequences of gene specific primers for human
MMP-9, IDO, COX-2, and β-actin were designed and pur-
chased from Invitrogen (Carlsbad, CA, USA) using PrimerPremier 5 and checked by Oligo 6 (Invitrogen). Expression
levels were normalized relative to the cell line according
to the formula 2-ΔΔCt, where Ct is the cycle threshold.
Statistical analysis
Statistical differences between data groups were determined
by independent t-tests using SPSS 19.0 software (SPSS Inc.,
Chicago, IL, USA). Data are expressed as mean ± SD;
P < 0.05 was considered statistically significant.
Results
Pancreatic cancer cells altered the percentages of surface
receptors and cytotoxic granules in NK cells
Nine surface receptors (CD16, NKG2D, DNAM-1, NKp30,
NKp44, NKp46, NKp80, KIR3DL1, and KIR2DL1/DS1)
and two cytotoxic granules (Perforin and Granzyme-B)
had been selected for investigation. Their levels and the
percentages of NK cells positive for each of these proteins
were determined after the NK cells had been cultured alone
or with hTERT-HPNE, BxPc-3 or SW1990 cells (Figure 1).
The percentages of NK cells positive for CD16, NKG2D,
DNAM-1, NKp30, NKp46, Perforin and Granzyme B were
significantly lower after exposure SW1990 cells compared
to NK cells cultured alone or co-cultured with normal
pancreatic hTERT-HPNE cells. Similarly, the percentages
of NK cells positive for DNAM-1, Perforin and Granzyme
B were also significantly downregulated following expos-
ure to BxPc-3 cells. However, there was no significant
change in the percentages of NK cells positive for activat-
ing surface receptors (NKp44 and NKp80) or inhibitory
surface receptors (KIR3DL1 and KIR2DL1/DS1) with
either of the pancreatic cancer cell lines. The significances
of these results are given in Figure 1 (P <0.05, P <0.01, or
P <0.001). These data suggested that pancreatic cancer
cells might induce NK cell dysfunction by targeting spe-
cific surface receptors and cytotoxic granules.
Pancreatic cancer cells induced apoptosis and
downregulated cytotoxic activity in NK cells
To investigate whether pancreatic cancer cells could
induce apoptosis in NK cells, NK cells were analyzed
after being cultured alone or co-cultured with normal pan-
creatic hTERT-HPNE cells or pancreatic cancer SW1990 or
BxPc-3 cells. As shown in Figure 2A and B, the percentages
Figure 3 (See legend on next page.)
Peng et al. BMC Cancer 2014, 14:738 Page 6 of 12
http://www.biomedcentral.com/1471-2407/14/738
(See figure on previous page.)
Figure 3 The expression of COX-2, MMP-9 and IDO in pancreatic cancer cells. (A) Relative expressions of COX-2, MMP-9 and IDO in hTERT-HPNE
cells compared to SW1990 cells cultured alone or co-cultured with NK cells. (B and C) The concentrations of IDO and MMP-9 in cell cultural
supernatants from NK cells cultured alone, hTERT-HPNE cells cultured alone or co-cultured with NK cells, SW1990 cells cultured aloneor co-cultured
with NK cells. (D and E) The corresponding plots for NK-92 cells cultured alone or cultured with SW1990, in the absence or presence of 0.5 mM 1-MT
and/or 0.5 ug/ml TIMP-1, show that the concentrations of IDO and MMP-9 can be partially restored by these blockers.All experiments were repeated
three times. All data were expressed as mean ± SD. Independent t-tests were used for statistical analysis through SPSS 19.0 software. *represents
P <0.05, **represents P <0.01, and ***represents P <0.001.
Table 1 The percentages of surface receptor- and
cytotoxic granule-positive NK-92 cells co-cultured with
SW1990 compared to those cultured alone
NK-92 +Medium (%) NK92 + SW1990 (%) P-value
NKG2D 94.72 ± 0.49 23.73 ± 2.05 <0.001
NKp30 27.36 ± 0.08 3.81 ± 0.17 <0.001
NKp44 24.33 ± 2.07 0.93 ± 0.48 <0.01
NKp46 11.76 ± 1.14 1.73 ± 1.03 <0.01
DNAM-1 51.35 ± 2.06 2.63 ± 1.13 <0.001
KIR3DL1 2.06 ± 0.65 1.78 ± 1.19 Ns
KIR2DL1/DS1 1.79 ± 0.96 2.50 ± 0.85 Ns
NKp80 92.67 ± 2.74 91.61 ± 2.85 Ns
Perforin 95.68 ± 0.52 40.93 ± 0.49 <0.001
Granzyme B 95.81 ± 1.96 86.24 ± 3.01 <0.01
All experiments were repeated three times. All data were expressed as mean ± SD.
Independent t-tests were used for statistical analysis through SPSS 19.0
software. P < 0.01 is considered significant; P < 0.001 is considered highly
significant.
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was significantly higher compared to those cultured alone
or with normal pancreatic hTERT-HPNE cells. However,
no significant difference was observed following exposure
to BxPc-3 cells.
The decreased percentages of NK cells positive for Per-
forin and Granzyme-B after exposure to SW1990 and
BxPc-3 suggested that pancreatic cancer cells could reduce
the cytotoxic activity of NK cells in vitro. Therefore, we in-
vestigated the cytotoxicity of NK cells against myelogenous
leukemia K562 cells. As shown in Figure 2C and D, the
cytotoxic activity of NK cells against K562 cells was
significantly downregulated following exposure to SW1990
cells or BxPc-3 cells at different E/T ratios, compared to
those cultured alone or with hTERT-HPNE cells. However,
the negative effect of SW1990 cells was greater than that of
BxPc-3 cells. These findings suggested that pancreatic
cancer cells could negatively influence the cytotoxic activity
of NK cells. This was most apparent with SW1990 cells.
Pancreatic cancer cells altered the concentration of
cytokines secreted by NK cells
In order to further understand the functional status of
NK cells following exposure to pancreatic cancer cells,
the concentrations of cytokines (GM-CSF, TNF-α and
IFN-γ) in the supernatants following cell culture were
determined by ELISA. As shown in Figure 2E to G, the
concentrations of GM-CSF secreted by NK cells following
exposure to BxPc-3 and SW1990 cells was significantly
increased, as determined by the lower levels of TNF-α,
compared to NK cells cultured alone or with normal
pancreatic hTERT-HPNE cells; however, the expression
of IFN-γ was only found to be downregulated in NK
cells that were exposed to SW1990 cells. These data
suggest that pancreatic cancer cells might also induce
NK cell dysfunction by impairing the secretion of
cytokines.
Overexpression of MMP-9 and IDO in SW1990 cells
treated with NK cells
Although we had demonstrated that pancreatic cancer
cells could induce NK cell dysfunction, the mechanisms
were unclear. Previous evidence had indicated that
MMP-9, IDO and COX-2 might be implicated in the
dysfunction of NK cells [16,20], therefore the expressionsof these proteins in SW1990 cells and hTERT-HPNE
cells cultured alone or co-cultured with NK cells was
investigated. Real-time qRT-PCR showed that the rela-
tive expression of MMP-9 and IDO was significantly
higher in SW1990 cells compared to normal pancreatic
hTERT-HPNE cells. However no significant difference was
observed in the expression levels of COX-2 (Figure 3A).
ELISA also showed that the concentrations of MMP-9
and IDO was markedly higher in supernatants from
SW1990 cells cultured alone compared to hTERT-HPNE
cells cultured alone; the concentrations of MMP-9 and
IDO was also higher in supernatants from SW1990 cells
co-cultured with NK cells compared to hTERT-HPNE
cells co-cultured with NK cells or NK cells cultured alone
(Figure 3B and C). These data suggested that MMP-9
and IDO might play a role in SW1990 cell-induced dys-
function of NK cells.
Blocking MMP-9 and/or IDO restored SW1990
cell-induced NK-92 cell dysfunction
To further confirm that MMP-9 and IDO were implicated
in SW1990 cell-induced NK cell dysfunction, NK-92 cells
were exposed to SW1990 cells and treated with specific
blockers for MMP-9 and IDO, TIMP-1 and 1-MT, respect-
ively. NK-92 cells were selected as they are more stable and
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the concentrations of MMP-9 and IDO were increased
in the supernatants from NK-92 cells co-cultured with
SW1990 cells compared to NK-92 cells cultured alone,
but decreased in the presence of TIMP-1 and/or 1-MT,
respectively (Figure 3D and E).
Furthermore, the percentages NK-92 cells positive for
NKG2D, NKp30, NKp44, NKp46, DNAM-1, Perforin and
Granzyme B following exposure to SW1990 cells wasFigure 4 The effect of MMP-9 and IDO blockers in NK-92 cells culture
and/or TIMP-1. (A) The percentages of NKG2D-, NKp30- and Perforin-posit
groups. (B, C and D) Comparisons between these different treatment groups
partially restore the percentage of positive NK-92 cells. All experiments were r
t-tests were used for statistical analysis through SPSS 19.0 software. *represensignificantly downregulated compared to NK-92 cells
cultured alone (Table 1). However, the levels of NKG2D-,
NKp30- and Perforin-positive NK-92 cells could be
partially restored following the introduction of TIMP-1
and/or 1-MT (Figure 4). A similar effect was observed
when the cytotoxic activity of NK-92 cells was investi-
gated. As shown in Figure 5A and B, blocking MMP-9
and/or IDO largely restored the cytotoxicity of NK-92
cells. The data also showed that blockade of MMP-9 byd alone or with SW1990 cells in the absence or presence of 1-MT
ive NK-92 cells in the different NK-92 cell-pancreatic cell treatment
demonstrate that the addition of 1-MT and/or TIMP-1 blockers can
epeated three times. All data were expressed as mean ± SD. Independent
ts P <0.05, **represents P <0.01, and ***represents P <0.001.
Figure 5 (See legend on next page.)
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Figure 5 Apoptosis in myelogenous leukemia K562 cells treated with NK-92 cells either cultured alone or with SW1990 cells in the
absence or presence of MMP-9 and/or IDO blockers. (A) Flow cytometric analysis of apoptosis in K562 cells treated with NK-92 cells with
1-MT and/or TIMP-1, at an effector-to-target (E/T) ratio 9:1. (B) The percentages of apoptotic K562 cells treated with NK-92 cells at different E/T
ratios (1:1, 3:1 and 9:1), show that the addition of 1-MT and/or TIMP-1 blockers upregulates apoptosis in K562 cells. (C, D, and E) Comparisons
between the concentrations of GM-CSF, TNF-α and IFN-γ in the supernatants from the different NK cell-pancreatic cell culture groups. All
experiments were repeated three times. All data were expressed as mean ± SD. Independent t-tests were used for statistical analysis through
SPSS 19.0 software. *represents P <0.05, **represents P <0.01, and ***represents P <0.001.
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and IFN-γ (Figure 5D and E), and blockade of IDO by
1-MT could restore the secretion of TNF-α (Figure 5D).
However, blockade by either MMP-9 and/or IDO showed
any significant effect on the level of GM-CSF. Further-
more, the effect of blocking MMP-9 and IDO simultan-
eously was significantly obvious in some aspects than that
of blocking IDO individually, but was similar to that of
blocking MMP-9 individually. Taken together, these data
provided further evidence that MMP-9 and IDO may play
key roles in SW1990 cell-induced NK-92 cell dysfunction,
however, there are no obvious synergic effects of MMP-9
and IDO.
Discussion
In a previous clinical trial, we found that the develop-
ment of pancreatic cancer was closely correlated with
tumor immune escape, mediated by dysfunction in the
circulating NK cells [28]. In this study, we found that NK
function was inhibited after exposure to pancreatic cancer
cells in vitro. This effect was greatest with SW1990 cells.
Further investigation showed that MMP-9 and IDO were
overexpressed in SW1990 cells and acted as negative
factors in SW1990 cell-induced NK cell dysfunction.
The association between NK cell dysfunction and altered
expression of surface receptors, cytotoxic granules and
cytokines has previously been reported in other cancers,
including melanoma and cervical cancer [29,30]. Activating
surface receptors induce cell stress apoptosis by binding to
specific ligands that are overexpressed on the surface of
stressed cells, including cancer cells. For example, MHC
class I polypeptide-related sequence A/B (MICA/MICB)
and UL16-binding protein (ULBP) bind to NKG2D [31];
whereas cellular heparin or heparin sulfate proteoglycans
bind to NCRs [32]. The cytotoxic granules Perforin and
Granzyme-B cooperatively combine to form a complex
which is released into the cytoplasm of infected cells and
tumor cells [33]. Cytokines TNF-α, IFN-γ and GM-CSF
are abundantly secreted by NK cells [34] and influence the
recruitment and function of other hematopoietic cells
(such as T cells) in the early stage of innate immune
responses [35].
Our findings showed that most of the surface receptors,
cytotoxic granules and cytokines discussed above were
significantly altered in NK cells following exposure topancreatic cancer cells. For example, lower expressions
of NKG2D, NKp30 and NKp46; downregulation of
Perforin and Granzyme-B; and decreased secretion of
TNF-α and IFN-γ. These data demonstrated that pancre-
atic cancer cells suppress NK cells through a variety of
mechanisms. However, increased secretion of GM-CSF in
NK cells may counteract the inhibiting effect of pancreatic
cancer cells on NK cells [36].
Inhibitory surface receptors remain hyporesponsive
in healthy bodies but are upregulated when the body
suffers infection or cancer to enable activated NK cells
to perform anti-tumor or anti-infection functions [37].
Two inhibitory surface receptors, KIR3DL1 and KIR2DL1/
DS1, were investigated in this study, however we found no
significant alteration in their expression in NK cells that
following exposure to pancreatic cancer cells.
Investigations into the mechanisms by which SW1990
cells might modulate NK cells revealed that SW1990 cells
produced high levels of negative soluble mediators when
co-cultured with NK cells, including MMP-9 and IDO.
Subsequent inhibition of MMP-9 and IDO could partially
restore NK cell function, suggested that these mediators
promoted pancreatic tumor growth by suppressing NK
cells.
MMP-9 promotes cancer progression through a var-
iety of mechanisms. Previous studies have reported that
MMP-9 decreased apoptosis in cancer cells [38]; reduced
proliferation and metastasis in cancer cells derived from
MMP-9 deficient mice compared to those from wild-type
mice [39,40]; promoted angiogenesis in two transgenic
models of cancer progression [38,39]; inhibited T cell
activity against tumors by enhancing IL-2Rα and TGF-
β production [41]; and could significantly suppress the
cytotoxicity of NK cells in oral squamous cell carcinoma
cell lines [20]. In support of these studies, we showed that
MMP-9 negatively influenced NK cell function through
decreased expression of NKG2D, NKp30 and Perforin and
inhibition of IFN-γ and TNF-α. Conversely, we showed
that inhibition of MMP-9 largely restored the levels of
NKG2D-, NKp30- and Perforin-positive NK-92 cells, the
secretion of TNF-α and IFN-γ and the cytotoxicity on NK
cells against myelogenous leukemia K562 cells. However,
our investigation was unable to determine whether
MMP-9 targeted NK cells directly or acted via other
pathways; for example, through promotion of IL-2Rα
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via stimulation of cytokines, such as interleukin-8 (IL-8),
connective-tissue activating peptide-III (CTAP-III), platelet
factor-4 (PF4) and growth-related oncogene-α (GRO-α),
which have previously been shown to alter infiltration and
migration of leukocytes [42].
IDO catalyzes the first and rate-limiting step in the
kynurenine pathway of tryptophan catabolism. Previous
studies have suggested that IDO contributes to immunoto-
lerance in patients with autoimmune diseases and chronic
infections [43,44], and that IDO expressed by hepatocellular
carcinoma-associated fibroblasts could induce NK cell
dysfunction in vitro [16]. Further studies have shown
that IDO can facilitate cancer cells to escape immune
surveillance by NK cells in cervical cancer [45] and by
regulatory T cells in pancreatic and breast cancer [46,47].
Our data has shown that IDO may promote the SW1990
cell-induced NK cell dysfunction by reducing the propor-
tion of NKG2D-, NKp30- and Perforin-positive NK-92
cells; and by downregulating the secretion of IFN-γ and
the cytotoxicity of NK cells against K562 cells. These
findings were similar to our results with MMP-9, and
there are no obvious synergic effects of MMP-9 and
IDO. Therefore, their relationship in relation to NK cell
dysfunction warrants further study.
The blocking effect of MMP-9 and IDO was incom-
plete suggesting that there may be additional factors
involved in SW1990 cell-induced NK cell dysfunction.
These could include PGE2, IL-8 and B7-H1 which have
been reported to be overexpressed and act as immuno-
suppressants by reducing the cytotoxicity of T cells and
NK cells in several solid cancers [48-50]. Increasing our
understanding of the underlying immunosuppressive
mechanisms and pathways could facilitate the develop-
ment of immune-dependent therapies for patients with
specific cancers.
Conclusions
In conclusion, our results have provided evidence that
pancreatic cancer cells induce NK cell dysfunction, how-
ever NK function could be partially restored by blocking
MMP-9 and/or IDO, suggesting that MMP-9 and IDO
facilitate pancreatic cancer cells to evade immuno-
surveillance. Although further study will be required to
determine the details of the mechanisms involved and
the interrelation between these molecules, our findings
could contribute to NK cell-based immunotherapy in
patients with pancreatic cancer.
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